Keryx Biopharma (KERX) – Press Releases
-
Cutera Announces Agreements with Pura Vida and RTW
-
Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics
-
Akebia Therapeutics Shareholders Approve Merger with Keryx
-
Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
-
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
-
Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
-
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
-
Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate — Research Highlights Growth,
-
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
-
Akebia Therapeutics Announces Third Quarter 2018 Financial Results
-
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results
-
Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018
-
Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
-
Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics
-
Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference
-
Akebia Therapeutics Announces Second Quarter 2018 Financial Results
-
Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results
-
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
-
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on Behalf of Stockholders and Encourages Investors to Contact the Firm
-
Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
-
Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st
-
Keryx Pharmaceuticals Announces Upcoming Investor Presentations
-
Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/E
-
Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results
-
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2018 Financial Results on Thursday, May 10, 2018
-
Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue
-
Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress
-
Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation
-
Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the
-
Keryx Biopharmaceuticals to Webcast its Presentation at the Cowen 38th Annual Healthcare Conference on March 12, 2018
-
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
-
Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018
-
Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 36th Annual Healthcare Conference on January 10, 2018
-
Consolidated Research: 2018 Summary Expectations for Schlumberger N.V, W.W. Grainger, Best Buy Co., Acadia Realty Trust, Keryx Biopharmaceuticals, and Gannett Co. — Fundamental Analysis, Key Perform
-
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017
-
U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
-
Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results
-
Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ET
-
Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN’s 2017 Kidney Week
-
Keryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia® (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney Diseas
-
Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2017 Financial Results on Monday, November 6, 2017
-
Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting
-
Keryx Biopharmaceuticals Announces Changes to its Board of Directors
-
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017
-
Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017
-
Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance
-
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017
-
Keryx Biopharmaceuticals to Webcast its Presentation at Jefferies’ 2017 Healthcare Conference on June 6, 2017
-
Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results
-
Keryx Announces that Auryxia® (Ferric Citrate) is Now on Formulary at All Major Medicare Part D Plans
Back to KERX Stock Lookup
